Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Receivables (2023 - 2025)

Metagenomi (MGX) has disclosed Receivables for 3 consecutive years, with $305000.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 75.74% to $305000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $305000.0 through Dec 2025, down 75.74% year-over-year, with the annual reading at $305000.0 for FY2025, 75.74% down from the prior year.
  • Receivables for Q4 2025 was $305000.0 at Metagenomi, down from $1.0 million in the prior quarter.
  • The five-year high for Receivables was $2.1 million in Q1 2024, with the low at $305000.0 in Q4 2025.
  • Average Receivables over 3 years is $1.2 million, with a median of $1.0 million recorded in 2025.
  • Peak annual rise in Receivables hit 69.78% in 2025, while the deepest fall reached 75.74% in 2025.
  • Over 3 years, Receivables stood at $2.0 million in 2023, then crashed by 37.15% to $1.3 million in 2024, then crashed by 75.74% to $305000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $305000.0, $1.0 million, and $900000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.